Our Story

Cancers are complex diseases that require personalized treatment approaches. A crucial element of delivering personalized care is the ability to monitor cancer by analyzing a patient’s blood sample and eliminating the need for invasive solid tumor biopsy procedures. “Liquid biopsies” enable routine sampling to detect the emergence of cancer, direct therapies and monitor treatment effectiveness.

We are revolutionizing cancer detection, management and cure with a proprietary technology platform that isolates and analyzes whole circulating tumor cells (CTCs). Starting with a non-invasive blood draw, the automated workflow unlocks rich, actionable CTC signatures, enabling screening of high-risk individuals, personalized therapy selection, routine monitoring, and disease management.

Arising from an affiliation between Massachusetts General Hospital Cancer Center and Johnson & Johnson, TorpedoDx was founded by a team of liquid biopsy pioneers. We are building on an exceptional foundation of clinical, technical, and organizational assets:

  • Premier clinical and R&D environment from close ties with the MGH Cancer Center

  • Thought-leading technical founders

  • Best-in-field CTC isolation technology

  • Imminent commercial readiness due to extensive development at MGH and J&J

We are currently building the infrastructure to offer centralized patient sample testing services and actively pursuing strategic collaborations with leading pharmaceutical companies, healthcare providers, and other institutions and agencies to enable clinical trials that capitalize on the unique, powerful utility of CTCs for liquid biopsy diagnostics.

Watch The Video

 Our Story

Cancers are complex diseases that require personalized treatment approaches. A crucial element of delivering personalized care is the ability to monitor cancer by analyzing a patient’s blood sample and eliminating the need for invasive solid tumor biopsy procedures. “Liquid biopsies” enable routine sampling to detect the emergence of cancer, direct therapies and monitor treatment effectiveness.

We are revolutionizing cancer detection, management and cure with a proprietary technology platform that isolates and analyzes whole circulating tumor cells (CTCs). Starting with a non-invasive blood draw, the automated workflow unlocks rich, actionable CTC signatures, enabling screening of high-risk individuals, personalized therapy selection, routine monitoring, and disease management.

Arising from an affiliation between Massachusetts General Hospital Cancer Center and Johnson & Johnson, TorpedoDx was founded by a team of liquid biopsy pioneers. We are building on an exceptional foundation of clinical, technical, and organizational assets:

  • Premier clinical and R&D environment from close ties with the MGH Cancer Center

  • Thought-leading technical founders

  • Best-in-field CTC isolation technology

  • Imminent commercial readiness due to extensive development at MGH and J&J

Watch The Video

We are currently building the infrastructure to offer centralized patient sample testing services and actively pursuing strategic collaborations with leading pharmaceutical companies, healthcare providers, and other institutions and agencies to enable clinical trials that capitalize on the unique, powerful utility of CTCs for liquid biopsy diagnostics.

 Our Solution

A tumor cell begins as a localized lesion in a specific tissue and as it grows, the tumor becomes invasive and begins to shed cells in the bloodstream. While the vast majority of these cells die, eventually, a small fraction will take hold in distant tissues, where they will proliferate and give rise to metastatic lesions. We can now access these cancer cells while they are in circulation with a simple blood draw (liquid biopsy) and interrogate them to guide treatment. Our approach leverages the rich information available from CTCs that will stand alone or complement other diagnostic methods.

The TorpedoDx CTC Isolator II platform employs sophisticated microfluidics to isolate as few as one CTC from a 10-ml tube of blood, allowing detection of cancer and the tissue of origin before metastases are established and providing a non-invasive tool for optimizing treatments.

A tumor cell begins as a localized lesion in a specific tissue and as it grows, the tumor becomes invasive and begins to shed cells in the bloodstream. While the vast majority of these cells die, eventually, a small fraction will take hold in distant tissues, where they will proliferate and give rise to metastatic lesions. We can now access these cancer cells while they are in circulation with a simple blood draw (liquid biopsy) and interrogate them to guide treatment. Our approach leverages the rich information available from CTCs that will stand alone or complement other diagnostic methods.

The TorpedoDx CTC Isolator II platform employs sophisticated microfluidics to isolate as few as one CTC from a 10-ml tube of blood, allowing detection of cancer and the tissue of origin before metastases are established and providing a non-invasive tool for optimizing treatments.

Compared to alternative methodologies, the TorpedoDx technology has utility and implications for a broad range of applications and features several significant advantages:

  • We achieve the highest possible sensitivity by isolating all tumor cells through selective removal of normal blood cells.

  • The technology is disease-agnostic. A single configuration enriches CTCs from all solid cancers.

  • Beyond simply detecting cancer, RNA and other contents of viable CTCs contain rich and actionable information including a holistic picture of the cancer identity and biological response to therapy.

  • We are ready for commercialization with a deployable and scalable workflow that delivers quantitative information in an automatable process.

The test workflow and liquid biopsy applications are in final stages of development and will soon be ready for widespread commercial adoption through partnerships with pharmaceutical companies, clinical centers, government institutions, and foundations.

 Our Team

Our leadership team combines an established track record of breakthrough scientific innovation and entrepreneurial success. The team features diverse backgrounds from leading academic institutions and genomics technology companies.

Founders

Daniel Haber, MD, PhD

Read Bio

Mehmet Toner, PhD

Read Bio

Ravi Kapur, PhD

Read Bio

Shyamala Maheswaran, PhD

Read Bio

Leadership

Darren Link, PhD

President and CEO

Brian Hutchison, PhD

Vice President of Development and Operations

Read Bio

Magali Soumillon, PhD

Lead Scientist and Director of Assay Development

 Career Opportunities

We are recruiting top scientific and business talent to join our team and quest to revolutionize the management of cancer and enable more prospects for cure. Contact us today to learn more jobs@torpedodx.com.

 Contact Us

We are headquartered inside the 70,000 square-foot LabCentral facility, a first-of-its-kind biotech innovation hub in Cambridge, Mass.

LabCentral
700 Main St. – North
Cambridge, MA 02139

info@TorpedoDx.com

Sign up today to join our growing community and receive email updates on our latest technology developments.

1 + 9 =